Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer
Treatment with intra-arterial gemcitabine led to an improvement in overall survival compared with continued treatment with intravenous gemcitabine plus nab-paclitaxel in patients with locally advanced pancreatic cancer following sequential treatment with IV gemcitabine, nab-paclitaxel, and radiotherapy.
Nivolumab/Ipilimumab Combo Provides Long-Term Survival Benefit in Advanced HCC After Sorafenib
The dual immunotherapy combination comprised of nivolumab given at 1 mg/kg and ipilimumab given at 3 mg/kg provided durable responses and long-term survival benefit in patients with advanced hepatocellular carcinoma following treatment with sorafenib.
Single-Agent Pembrolizumab Maintains Survival Benefit in Sorafenib-Pretreated Advanced HCC
Pembrolizumab monotherapy continued to demonstrate durable antitumor activity with promising overall survival in patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib, according to updated data from cohort 1 of the phase 2 KEYNOTE-224 trial.
Panitumumab Plus mFOLFOX6 Improves Survival in RAS Wild-Type mCRC
August 12th 2022Treatment with frontline panitumumab and mFOLFOX6 led to a significant improvement in overall survival, plus higher response rates and R0 resection rates, compared with bevacizumab and mFOLFOX6 in patients with RAS wild-type metastatic colorectal cancer.
Tucatinib Plus Trastuzumab Induces Durable Tumor Response in HER2+ mCRC
July 2nd 2022Patients with previously treated metastatic HER2-positive colorectal cancer experienced clinically meaningful and durable responses to treatment with tucatinib plus trastuzumab, according to data from the phase 2 MOUNTAINEER trial.
Tremelimumab/Durvalumab Produces Favorable OS Benefit in Unresectable HCC Irrespective of ALBI Grade
A single priming dose of tremelimumab added to regular interval durvalumab generated significantly improved overall survival compared with sorafenib in the frontline setting for patients with unresectable hepatocellular carcinoma, irrespective of of their baseline albumin-bilirubin grade, according to updated data from the phase 3 HIMALAYA trial.
Tislelizumab Plus Chemotherapy Elicits Strong Survival Benefit in Esophageal Cancer
June 30th 2022The combination of tislelizumab and chemotherapy demonstrated a superior overall survival benefit compared with chemotherapy alone in patients with metastatic or unresectable esophageal squamous cell carcinoma
Durvalumab Plus Chemotherapy Maintains OS Benefit in Advanced Biliary Tract Cancer
June 30th 2022The addition of durvalumab to gemcitabine and cisplatin demonstrated an improvement in overall survival vs gemcitabine and cisplatin plus placebo as frontline therapy in patients with advanced biliary tract cancer, regardless of primary tumor location.
Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC
The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.
Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC
A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.
Later-Line Infigratinib Outperforms Standard Chemotherapy in Cholangiocarcinoma
July 3rd 2020Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.
EDP1503 With or Without Pembrolizumab Has Clinical Activity Across Solid Tumors
July 3rd 2020EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.
Maintenance Olaparib Maintains Benefit in Metastatic Pancreatic Cancer, Regardless of Age
July 2nd 2020The safety and efficacy of maintenance olaparib in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial.